Home / Guides / Public Citizen report
News

Public Citizen Report: FDA Looked the Other Way on Unapproved Peptides (21 November 2026)

Published 21 November 2026 · For laboratory research and education only
Research use only · Not medical advice
Public Citizen: FDA looked the other way on peptides: What the “Asleep at the Vial” report found

Public Citizen, the US consumer advocacy group, published a report on 19 November 2026 titled “Asleep at the Vial: FDA Looked the Other Way as Unapproved Peptide Sales Boomed”. Written by Peter Whoriskey, research director of its Health Research Group, it argues that the FDA had already stopped policing unapproved peptides long before HHS announced its October policy on compounding six of them.

Below: what the report found, how it connects to the HHS policy, and what it means for laboratories that buy research-use-only peptides.

What the Public Citizen report found

  • More than 150 FDA warning letters went to companies marketing unapproved substances since the start of the second Trump administration. The report says only one concerned a seller of one of the six peptides now covered by HHS, and that company had already agreed to shut down for other reasons.
  • At least 11 companies that received FDA warnings for selling unauthorized GLP-1 weight-loss drugs also sold at least one of the six peptides; the warning letters did not mention the peptides.
  • Citing blockchain analytics firm TRM Labs, the report says about 100 of the more than 200 companies found selling fentanyl precursors also sold peptides such as BPC-157, TB-500 and Epitalon.
  • Past enforcement did happen: one compounding company agreed to forfeit $1,788,906.82 tied to its 2019 peptide sales, and in July 2026 the owner of a peptide company was sentenced to 70 months in prison.
  • The report concludes that enforcement against unapproved peptides “ground to a halt” in 2025, and that the October 2026 HHS policy formalised an approach the FDA had already taken.

Our running list of letters sent to peptide sellers: FDA peptide warning letters.

How the report connects to the HHS peptide policy

In late October 2026 HHS announced an interim enforcement discretion policy for 503A pharmacies compounding six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The report points out that FDA’s Pharmacy Compounding Advisory Committee voted in July 2026 to recommend them for the 503A bulks list, while FDA staff scientists had recommended against each one, citing limited evidence. It quotes HHS Secretary Robert F. Kennedy Jr.: “Americans are going to be buying these anyway.”

Background on the policy: the HHS peptide compounding policy, the comment period that closed on 13 November, and Hims & Hers and Noom entering the market.

What the report does and does not say

PointWhat the report saysWhat it does not say
FDA enforcementLargely stopped for peptides in 2025That peptides are now approved or legal for human use
HHS policyFormalised an existing hands-off approachThat research-use-only sales are covered (they are not)
Supply chainOverlap between peptide and fentanyl-precursor sellersThat every peptide seller is part of that overlap
TestingIndependent testers such as Finnrick and Janoshik publish resultsThat any supplier is safe for human use

What it means for research labs

If regulators are not checking the market, the burden of checking falls on the buyer. For laboratory work that means:

  • Lot-matched COAs: the lot number on the vial must appear on the certificate. Guide: how to verify a peptide COA.
  • Identity and quantity: mass-spectrometry identity and measured net content, not only an HPLC purity figure. See HPLC vs mass spec.
  • No human-use marketing: suppliers that make dosing or health claims are the ones that attract warning letters. Our criteria: how we verify suppliers.
  • Legal status by country: are peptides legal?

What to watch next

  • Whether HHS finalises, changes or withdraws the interim policy after reviewing public comments.
  • FDA’s formal rulemaking on the 503A bulks list for the six peptides.
  • Any return of FDA or DOJ enforcement against sellers making human-use claims.
  • Further reports from Public Citizen’s Health Research Group, which also published on unapproved retatrutide products in June 2026.

Frequently asked questions

A report by Peter Whoriskey, research director of Public Citizen’s Health Research Group, dated 19 November 2026. Its full title is “Asleep at the Vial: FDA Looked the Other Way as Unapproved Peptide Sales Boomed”. It argues that FDA enforcement against unapproved peptides had largely stopped before HHS announced its October 2026 compounding policy.

More than 150 warning letters to companies marketing unapproved substances since the start of the second Trump administration. According to the report, only one went to a company selling one of the six peptides in the HHS policy, and that company had already agreed to shut down for other reasons.

The six peptides covered by the HHS interim enforcement discretion policy: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The report notes that FDA staff scientists had recommended against adding each of them to the 503A bulks list.

No. It is an advocacy report, not a rule. Research peptides remain unapproved and are sold for laboratory research only; the HHS policy covers only patient-specific compounding by 503A pharmacies under ten conditions.

That weak enforcement does not mean quality is checked by anyone. Labs should rely on lot-matched certificates of analysis from named laboratories, identity testing by mass spectrometry and measured net content, and should avoid suppliers that make human-use claims.

Deal of the week50% off research peptides

Code IZBA50OFF at Ascension Peptides (US).

Get 50% off now →See all codes and pricesAd · affiliate link · Research use only

Free PDF: November peptide codes + price-per-mg sheet

All 15 supplier codes and the lowest price per mg for 14 research compounds, on 2 pages. Updated monthly. For laboratory research use only.

No spam. Unsubscribe any time. Read our privacy policy.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.
You need to agree with the terms to proceed

Managed by Teeztech Agency